Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo?

• Conditions: ischemia reperfusion injury; myocardial infarction; 10011082

• Registration Number: NL-OMON30203
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

-Male
-Age 18-50 years
-Informed consent
-Physical able to perform ischemic exercise

Exclusion Criteria

-History of any cardiovascular disease
-Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg)
-Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
-Hyperlipidaemia (random total cholesterol > 6 mmol/l)
-Alanine-Amino-Transferase (ALAT) >90 U/L (more than twice the upper level of the normal range)
-Creatinine Kinase (CK) >340 U/L (more than twice the upper level of the normal range)
-Drug abuse
-Concomitant chronic use of medication
-Administration of radioactivity in research setting during the last 5 years
-Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Annexin A 5 targeting in the non dominant thenar muscle after ischemic<br /><br>exercise, as a indicator for ischemia reperfusion injury</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Fasting lipid profile before and after three day therapy with atorvastatin<br /><br>80mg. Workload performed during ischemic exercise.</p><br>